Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
July 23 2021 - 7:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal
trial in Alzheimer’s disease with top-line data expected in the
fourth quarter of 2021 and a growing pipeline of therapeutics for
degenerative diseases, announced the selection of a lead 3CLpro
inhibitor (COR803) for treatment of coronavirus infections,
including COVID-19 disease, caused by SARS-CoV-2 infection.
“There continues to be a large unmet need for coronavirus
treatment. The target of COR803 is highly conserved across variants
and among coronaviruses in general, therefore it is expected to
address both current and future coronavirus strains, including the
delta variant of SARS-CoV-2,” said Casey Lynch, Cortexyme’s chief
executive officer, co-founder, and chair. “We have selected COR803
based on compelling data to support its development as a potential
therapy that could be prescribed at the first sign of infection or
after known exposures without requiring patients to be
hospitalized, as well as for those in critical care. The novel
characteristics of COR803 reflect the breadth and capabilities of
our proprietary research and development as Cortexyme continues to
apply our innovative science to areas of high clinical need.”
COR803 is a novel patent-pending small molecule 3CLpro inhibitor
discovered and developed by Cortexyme based on its expertise in
cysteine protease inhibition. 3CLpro, or Mpro, is a validated
antiviral drug target shown to be essential in viral replication of
SARS-CoV-2. COR803 has beneficial properties over other COVID-19
therapeutics and 3CLpro inhibitors in development including:
- Covalent irreversible binding of the viral 3CLpro enzyme;
- High potency: Antiviral EC90 of 30 nM in human lung cell viral
replication assays;
- Highly selective for 3CLpro versus other cellular proteases
including Cathepsin L; and
- Excellent systemic exposure utilizing intranasal or
subcutaneous administration, allowing for clinical use in multiple
settings such as outpatient and inpatient.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
Alzheimer’s and other degenerative diseases. The company is
advancing its disease-modifying pivotal GAIN Trial in mild to
moderate Alzheimer's disease with top-line data expected in the
fourth quarter of 2021, in addition to growing a proprietary
pipeline of first-in-class small molecule therapeutics for
Parkinson’s disease, periodontitis, and other diseases with high
unmet clinical need. Cortexyme’s lead program targets a specific,
infectious pathogen called P. gingivalis found in the brain and
other organs and tied to degeneration and inflammation in humans
and animal models. The company’s causation evidence for Alzheimer’s
disease and the mechanism of its novel therapeutic has been
independently replicated and confirmed by multiple laboratories
around the world, as well as published in peer-reviewed scientific
journals. To learn more about Cortexyme, visit www.cortexyme.com or
follow @Cortexyme on Twitter.
Forward-Looking Statements
Statements in this news release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this news
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast,” or other similar words. Examples
of forward-looking statements include, among others, statements we
make regarding our business plans, strategy, timeline, prospects,
and milestone expectations; the characteristics and potential
benefits of COR803, including for the treatment of coronavirus
infections, the timing and success of the company’s clinical trials
and related data; the potential of atuzaginstat to treat
Alzheimer’s disease, periodontal disease, and other potential
indications; the timing of announcements and updates relating to
its clinical trials and related data; the potential therapeutic
benefits, safety and efficacy of the company’s product candidate or
library of compounds; and statements about its ability to obtain,
and the timing relating to, regulatory submissions and approvals
with respect to the company’s drug product candidate.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks, and
assumptions that are difficult to predict and could cause actual
results to differ materially from what the company expects.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in Cortexyme’s Annual Report on Form
10-K filed with the Securities and Exchange Commission (SEC) on
March 1, 2021, its Quarterly Report on Form 10-Q filed with the SEC
on May 6, 2021, and other reports as filed with the SEC.
Forward-looking statements contained in this news release are made
as of this date, and Cortexyme undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210723005073/en/
Cortexyme Contact: Stacy Roughan Cortexyme, Inc. Vice
President, Corporate Communications & Investor Relations
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024